Hyperlipidemia Drugs Market (2026 - 2033)

Hyperlipidemia Drugs Market Summary

The global hyperlipidemia drugs market size was valued at USD 24.4 billion in 2025 and is projected to grow from USD 25.1 billion in 2026 to USD 30.2 billion in 2033, at a CAGR of 2.7% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 40.0% in 2025. The key factors include the increasing prevalence of cardiovascular diseases and technological advancements that have led to the development of new drugs. In addition, the rise in the geriatric population with a higher prevalence of hyperlipidemia and associated cardiovascular risks has created a need for potent drugs and novel therapies.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Key Market Trends & Insights

• By drug class: The statins segment held the largest market share of around 45.0% in 2025.
• By route of administration: The oral segment held the largest market share of over 60.0% in 2025.
• By distribution channel: The retail pharmacies segment held the largest market share of around 50.0% in 2025.

Regional Highlights

• Largest regional market: North America (40.0% revenue share, 2025)
• Fastest-growing regional market: Asia Pacific (highest CAGR, 2026-2033)

Market Size & Forecast

• Market size in 2025: USD 24.4 Billion
• Estimated market size in 2026: USD 25.1 Billion
• Projected market size by 2033: USD 30.2 Billion
• CAGR (2026-2033): 2.7%

The growing awareness of the risks associated with high cholesterol levels, the importance of managing lipid profiles, and competition among market players have encouraged market development. The increasing incidences of hyperlipidemia, sedentary lifestyles, and poor diets have resulted in higher lipid levels in the global population. Furthermore, awareness of high cholesterol and its impact on cardiovascular diseases, as well as rising healthcare expenditure for better treatment of conditions such as hyperlipidemia, further help market growth. In addition, disposable income has led patients to opt for better treatment, further propelling market growth.

Hyperlipidemia is one of the causes of cardiovascular diseases. Under such conditions, elevated levels of lipoprotein can lead to stroke. Second to smoking, hyperlipidemia is a major cause of heart disease, resulting in stroke or cardiac arrest. Research initiatives to develop novel drug classes create new opportunities for drug development. For instance, PCSK9 inhibitors such as alirocumab (Praluent) and evolocumab (Repatha) are gaining popularity due to their performance in such cases. These drugs have shown efficacy in lowering low-density lipoprotein (LDL), or bad cholesterol, in patients with cardiovascular disease. Moreover, advances in gene therapy present long-term treatment opportunities for patients. These therapies are efficient in targeting genetic mutations that trigger hypercholesterolemia.

Analyst Perspective

The market is experiencing steady growth, driven by the increasing prevalence of cardiovascular diseases, rising incidence of high cholesterol, and growing awareness of preventive heart health management. The rising number of aged individuals, a sedentary lifestyle, and high obesity and diabetes prevalence are contributing to the expansion of the market. Moreover, innovations in lipid-lowering medications, combination therapies, and biologics are making treatment more effective and diverse for patients. As demand for safe, effective, and long-term cardiovascular disease management continues to rise, companies that focus on innovative drug development, clinical research, and patient-centric treatment solutions will be well-positioned to capture long-term growth opportunities.

Drug Class Insights

The statins segment held the largest market share of around 45.0% in 2025. The increasing prevalence of cardiovascular diseases, including heart attacks and strokes, growing awareness regarding preventive health checkups, particularly among the geriatric population, and recommendations from clinical practice guidelines continue to support the widespread use of statins. In addition, the expanding elderly population and ongoing investments in cardiovascular research are expected to create growth opportunities for the segment. Continuous improvements in statin formulations and treatment strategies have enhanced tolerability and long-term adherence. Statins also remain a cornerstone of lipid-lowering therapy alongside lifestyle modifications, dietary management, and regular physical activity.

The PCSK9 inhibitors segment is expected to register the fastest CAGR during the forecast period. The segment is driven by the strong clinical efficacy of PCSK9 inhibitors in lowering low-density lipoprotein cholesterol (LDL-C), reducing cardiovascular risk, increasing regulatory approvals, and the rising prevalence of hyperlipidemia. Continued investments in next-generation lipid-lowering therapies are also supporting market growth. For instance, in August 2025, Amgen announced that the U.S. Food and Drug Administration (FDA) had expanded the approved indication for Repatha (evolocumab) to include reducing the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease. The label expansion reflects the increasing clinical adoption of PCSK9 inhibitor therapies for comprehensive cardiovascular risk management.

Route of Administration Insights

The oral segment held the largest market share of over 60.0% in 2025. Oral lipid-lowering therapies remain the preferred treatment option due to their ease of administration, high patient compliance, broad availability, and cost-effectiveness. Oral formulations, including tablets and capsules, are widely prescribed for long-term cholesterol management and are often used in combination with lifestyle interventions or other lipid-lowering agents to improve treatment outcomes.

The parenteral segment is expected to witness the fastest CAGR over the forecast period. Factors such as rapid therapeutic action, high efficacy in patients requiring intensive LDL-C reduction, and continuous innovations in injectable biologic therapies are expected to drive segment growth. Increasing adoption of monoclonal antibodies and other advanced injectable lipid-lowering therapies is further supporting market expansion. For instance, in January 2025, the European Commission extended the approval of Evkeeza (evinacumab) to include pediatric patients aged six months and older with homozygous familial hypercholesterolemia (HoFH). The expanded indication increases access to this injectable lipid-lowering therapy while highlighting the growing importance of parenteral treatment options for the management of severe hyperlipidemia.

Distribution Channel Insights

The retail pharmacies segment held the largest market share of around 50.0% in 2025. The segment is driven by widespread accessibility, convenient prescription fulfillment, pharmacist-led patient counseling, and integration with healthcare providers to support medication adherence. Retail pharmacies continue to play a key role in the long-term management of hyperlipidemia by improving patient access to prescription lipid-lowering medications while operating under established regulatory standards.

The online pharmacies segment is expected to witness the fastest CAGR during the forecast period. Increasing internet penetration, improved digital healthcare infrastructure, competitive pricing, and the growing preference for home delivery of prescription medicines are supporting market growth. The expansion of digital pharmacy platforms and e-prescription services is expected to enhance patient convenience further and improve access to long-term lipid-lowering therapies.

Regional Insights

North America held the largest market share of around 40.0% in 2025, driven by the rising prevalence of hyperlipidemia, the growing geriatric population, well-established healthcare infrastructure, and increasing investments in cardiovascular research and drug development. Rising disposable income and greater public awareness regarding cholesterol management and cardiovascular disease prevention are further supporting market growth. For instance, in June 2025, Eli Lilly announced a definitive agreement to acquire Verve Therapeutics to strengthen its portfolio of investigational genetic medicines for cardiovascular disease, including gene-editing therapies targeting cholesterol-related disorders, reinforcing continued investment in next-generation hyperlipidemia treatments.

To learn more about this report, Download Free Sample Report

U.S. Hyperlipidemia Drugs Market Trends

The hyperlipidemia drugs market in the U.S. is expected to grow significantly during the forecast period. The increasing prevalence of hyperlipidemia, the widespread availability of advanced healthcare services, favorable reimbursement policies, and growing public awareness of cardiovascular risk factors continue to support market growth. In addition, strong pharmaceutical research activities and the ongoing development of novel lipid-lowering therapies are expected to strengthen the market further.

Asia Pacific Hyperlipidemia Drugs Market Trends

The hyperlipidemia drugs market in the Asia Pacific is expected to register the fastest CAGR during the forecast period. Rising prevalence of hyperlipidemia, rapid population aging in countries including China, Japan, and India, increasing healthcare expenditure, and improving access to cardiovascular care are expected to drive market growth. Government initiatives to strengthen chronic disease management and growing awareness of cholesterol screening are also supporting demand for lipid-lowering therapies.

Europe Hyperlipidemia Drugs Market Trends

The hyperlipidemia drugs market in Europe is expected to grow steadily during the forecast period, driven by the rising prevalence of hyperlipidemia, particularly familial hypercholesterolemia, supportive healthcare policies, and increasing investments in cardiovascular research. Continued funding for innovative therapies and collaborative research initiatives is expected to improve treatment accessibility across the region.

Key Hyperlipidemia Drugs Company Insights

Some key companies in the market are AstraZeneca, Merck & Co., Inc., and others. Organizations focus on increasing their customer base to gain a competitive edge in the industry. Therefore, key players are taking several strategic initiatives, such as mergers and acquisitions, and partnerships with other major companies. 

• AstraZeneca is a British-Swedish company with a broad portfolio in medical science. It has produced widely accepted innovative drugs for hyperlipidemia. AZD0780 is the first small oral molecule, PCSK9 inhibitor developed by AstraZeneca for patients with hyperlipidemia.
• Merck & Co. is a U.S.-based company with expertise in hyperlipidemic medications that focus on lowering low-density lipoprotein cholesterol.

Key Hyperlipidemia Drugs Companies

The following are the leading companies in the hyperlipidemia drugs market. These companies collectively hold the largest market share and dictate industry trends.

• AstraZeneca

• Merck & Co., Inc.

• Pfizer Inc.

• DAIICHI SANKYO COMPANY LIMITED

• Amgen Inc.

• Sanofi

• Viatris Inc.

• Esperion Therapeutics, Inc.

Recent Developments

• In May 2024, research from the Baylor College of Medicine showed the effect of drug (Plozasiran) therapy on hyperlipidemia. Plozasiran targets ApoC3, which regulates lipoprotein particles that carry triglycerides and cholesterol.
• In March 2024, the U.S. Food and Drug Administration (FDA) approved Praluent (alirocumab) for use in pediatric patients with high cholesterol, enabling earlier intervention to reduce and manage low-density lipoprotein cholesterol (LDL-C) levels. The approval supports the expanding role of injectable lipid-lowering therapies in the early management of dyslipidemia.

Global Hyperlipidemia Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hyperlipidemia drugs market report based on drug class, route of administration, distribution channel, and region:

• Drug Class Outlook (Revenue, USD Million, 2021 - 2033)

  • Statins

  • Bile Acid Sequestrants

  • Cholesterol Absorption Inhibitors

  • Fibric Acid Derivatives

  • PCSK9 Inhibitors

  • Combination

  • Miscellaneous

• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)

  • Oral

  • Parenteral

  • Others

• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospital Pharmacies

  • Online Pharmacies

  • Retail Pharmacies

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • Saudi Arabia

    • UAE

    • Kuwait

    • South Africa